Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

44.51 -0.49 (-1.09%)

Streaming Delayed Price Updated: 1:44 PM EST, Mar 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

41 42 Next >

Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch ↗

October 24, 2023

Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating.

Via Investor's Business Daily

Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments

October 24, 2023

EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space ↗

October 23, 2023

Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.

Via Investor's Business Daily

(SNY) - Analyzing Sanofi's Short Interest ↗

October 09, 2023

Via Benzinga

What's Going On With Mirati Therapeutics Stock? ↗

October 06, 2023

Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are trading higher Friday.

Via Benzinga

Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market? ↗

October 23, 2023

Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises.

Via Benzinga

Topics Stocks

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

October 22, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Sanofi Bridging the Gap between the Homeless and Society via Futsal

October 17, 2023

From sanofi-aventis Korea

Via Business Wire

Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants ↗

October 16, 2023

As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ:

Via Benzinga

2 Healthcare Stocks Near 52-Week Highs Still Worth Buying ↗

October 16, 2023

These two large-cap biopharma companies could have more room to run.

Via The Motley Fool

Week In Review: Two China Biopharmas Announce Billion Dollar Deals ↗

October 14, 2023

MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with...

Via Talk Markets

2 Surefire Stocks That Could Make You Richer ↗

October 11, 2023

It won't happen overnight, but with these stocks, a little patience is all you need.

Via The Motley Fool

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid ↗

October 09, 2023

Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion.

Via Investor's Business Daily

Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts ↗

October 06, 2023

According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX).

Via Benzinga

Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories ↗

October 04, 2023

Benzinga

Via Benzinga

Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble. ↗

October 04, 2023

The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck.

Via Investor's Business Daily

Sanofi, Teva Pledge $1.5B To Target Inflammatory Bowel Disease That Impacts Almost 10M People ↗

October 04, 2023

Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and

Via Benzinga

Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update ↗

October 04, 2023

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c

Via Benzinga

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

October 04, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Why Shares of Kymera Therapeutics Jumped on Tuesday ↗

October 03, 2023

The company had a big bounce after hitting a 52-week low the day before.

Via The Motley Fool

'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories ↗

October 03, 2023

Benzinga

Via Benzinga

Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine ↗

October 03, 2023

Sanofi SA (NASDAQ: SNY) struck a deal with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ), to develop and commercialize the vaccine candidate for extraintestinal&nb

Via Benzinga

AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug ↗

October 03, 2023

AstraZeneca Plc (NASDAQ: AZN) has

Via Benzinga

Topics Lawsuit

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗

October 02, 2023

Read the latest report on NanoViricides here

Via Benzinga

Stock Split Watch: Is Regeneron Pharmaceuticals Next? ↗

September 30, 2023

If the biotech does split its stock, it will be a first for the company.

Via The Motley Fool

Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst ↗

September 28, 2023

Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.

Via Benzinga

Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories ↗

September 27, 2023

Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO

Via Benzinga

Topics Artificial Intelligence

Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate ↗

September 27, 2023

The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE

Via Benzinga

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗

September 26, 2023

Read the latest report on NanoViricides here

Via Benzinga

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

September 26, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.